



*"We are committed to save lives."*



September 26<sup>th</sup>, 2013

## Press release

### **HEMARINA and LFB Biomanufacturing announced the signature of an agreement for the manufacturing of HEMO<sub>2</sub>life®**

Morlaix and Alès (France) – September 26<sup>th</sup>, 2013 - HEMARINA, a French based marine biotechnology company dedicated to the R&D of universal oxygen carrier solutions, signed an industrial subcontracting agreement with LFB Biomanufacturing, LFB group's subsidiary specialized in the manufacturing of active protein solutions for pharmaceutical applications, leading up to the preparation of HEMO<sub>2</sub>life® regulatory batches.

The HEMO<sub>2</sub>life® is a major breakthrough innovation in the field of organ preservation solutions. This product developed by HEMARINA enables preservation of organs and tissues under optimal physiological conditions due to oxygen contribution essential to their survival. Indeed, once the organ is removed from the donor it will go through an ischaemia/reperfusion cycle that could induce lesions and graft failures after transplant. HEMO<sub>2</sub>life® can make up for these two major issues during transplant as an oxygen carrier is facing free radicals during reperfusion.

The pre-clinical results induced and published in the international journal American Journal of Transplantation (2011; 11: 1845–1860) showed the graft preservation with HEMO<sub>2</sub>life®, compared with clinical use solutions, induces fast resumption of normal function and extended preservation time on renal cellular model.

*"It is a real satisfaction for LFB Biomanufacturing to offer its expertise and abilities enabling the preparation of this unique product dedicated to organs and tissues preservation,"* says Roland Béliard, Chairman of LFB Biomanufacturing.

The first batches of this extraction hemoglobin will be issued at the end of 2013 and the beginning of 2014 from Alès plant (Gard).

*"This agreement is also a real opportunity for us to manufacture locally a therapeutic solution developed by an innovative French based biotechnology company."*

*"We are very pleased with this agreement signed with LFB Biomanufacturing, subsidiary of the LFB group. This is a crucial step for HEMARINA, willing to capitalise on the outstanding outlets offered by HEMO<sub>2</sub>life® and to work with a major French biopharmaceutical group for this type of solution which significantly increases engraftment success. Organ is so valuable that a special attention must be given to its preservation conditions, not only for the patient but also for the donor family." says Dr Franck Zal, CEO and co-founder of HEMARINA.*



*"We are committed to save lives."*

### **About LFB Biomanufacturing**

**LFB Biomanufacturing** is a company specialized in the development and the manufacturing of recombinant proteins through cell culture, with a specific know-how in the field of monoclonal antibodies.

**LFB Biomanufacturing** can provide a full range of bioproduction services, including cell lines development, research and manufacturing of cell production and purification processes as well as manufacturing of clinical and commercial batches of active substances for biological. (<http://www.lfbbiomanufacturing.com>)

**LFB Biomanufacturing** is an LFB group's subsidiary, the leading manufacturer of plasma-derived medicinal products in France, 5th worldwide and also among the leading European companies for the development of new-generation proteins and treatments based on biotechnologies. In 2012, the Group had 1,887 employees and generated a total turnover of € 466 million.

<http://www.lfb.fr>

#### Press contact

Sandrine Charrières, Corporate communications director

+33 169 827 280

[charrieres@lfb.fr](mailto:charrieres@lfb.fr)

### **About HEMARINA**

**HEMARINA** is a biotechnology start-up based in Morlaix (Finistère, France), developing innovative solutions based on marine molecules for patients and healthcare industry. These universal oxygen carriers' molecules are developed for various therapeutic and industrial applications. **HEMARINA** has four core research programs which all of them are patented breakthrough innovations: organs transplantation and tissues conservation, blood substitutes, infections and wound healing as well as bio-production. **HEMARINA** core assets and know-how are based on a world-renowned scientific expertise coupled with its unique positioning of innovative solutions provider meeting public health issues requirements.

For more information about HEMARINA, please visit [www.hemarina.com](http://www.hemarina.com)

#### HEMARINA Contacts

**Address:** Aéroport centre, 29600 Morlaix, France

**Phone:** +33 298 881 402

**E-mail:** [media@hemarina.com](mailto:media@hemarina.com)

**Website:** [www.hemarina.com](http://www.hemarina.com)

**Twitter:** @HEMARINA

**Facebook:** [www.facebook.com/HemarinaBiotech](http://www.facebook.com/HemarinaBiotech)